Profund Advisors LLC boosted its position in Zoetis Inc. (NYSE:ZTS) by 3.1% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 31,095 shares of the company’s stock after purchasing an additional 921 shares during the period. Profund Advisors LLC’s holdings in Zoetis were worth $1,940,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. BT Investment Management Ltd acquired a new stake in Zoetis during the second quarter worth approximately $565,000. Amalgamated Bank lifted its position in Zoetis by 65.0% during the second quarter. Amalgamated Bank now owns 57,944 shares of the company’s stock worth $3,615,000 after acquiring an additional 22,830 shares during the last quarter. BlackRock Inc. lifted its position in Zoetis by 3.9% during the second quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock worth $2,338,957,000 after acquiring an additional 1,412,829 shares during the last quarter. Bahl & Gaynor Inc. lifted its position in Zoetis by 1.9% during the second quarter. Bahl & Gaynor Inc. now owns 21,704 shares of the company’s stock worth $1,162,000 after acquiring an additional 407 shares during the last quarter. Finally, Comerica Securities Inc. lifted its position in Zoetis by 2.5% during the second quarter. Comerica Securities Inc. now owns 10,508 shares of the company’s stock worth $657,000 after acquiring an additional 260 shares during the last quarter. Institutional investors and hedge funds own 93.20% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/18/zoetis-inc-zts-position-raised-by-profund-advisors-llc.html.

Zoetis Inc. (NYSE ZTS) traded down 0.29% during midday trading on Monday, hitting $65.01. 151,792 shares of the stock were exchanged. The firm’s 50-day moving average price is $62.29 and its 200 day moving average price is $59.39. The firm has a market capitalization of $31.80 billion, a P/E ratio of 36.75 and a beta of 1.02. Zoetis Inc. has a 1-year low of $46.86 and a 1-year high of $65.83.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.53. The company had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. Zoetis’s revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.49 EPS. Analysts expect that Zoetis Inc. will post $2.34 earnings per share for the current fiscal year.

Several brokerages have issued reports on ZTS. Cantor Fitzgerald restated a “buy” rating and set a $75.00 price objective on shares of Zoetis in a research report on Wednesday, September 6th. Hilliard Lyons began coverage on shares of Zoetis in a research report on Tuesday, June 20th. They set a “buy” rating and a $77.00 price objective for the company. Credit Suisse Group raised their price objective on shares of Zoetis from $61.00 to $67.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 24th. Zacks Investment Research downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. Finally, Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $62.00 price objective on shares of Zoetis in a research report on Monday, August 7th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $65.44.

Zoetis Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.